Shinya Yokomizo

Shinya Yokomizo

Auto-generated profile, based on publicly available information

Shinya Yokomizo

Massachusetts General Hospital (United States)

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2021 in View
Verified
Journal Article
Open access
PDF file
HMHailey Monaco
Hailey Monaco
SYShinya Yokomizo
Shinya Yokomizo
Hak Soo ChoiHak Soo Choi
Hak Soo Choi
Satoshi KashiwagiSatoshi Kashiwagi
Satoshi Kashiwagi
Among modalities of cancer immunotherapy, near‐infrared photoimmunotherapy (NIR‐PIT) has reached significant preclinical and clinical stages and quickly evolved over the last 5 years. NIR‐PIT uses deep‐penetrable NIR light to induce physicochemical changes in the antibody–photosensitizer conjugate (APC), leading to resultant necrosis and immunogenic cell death (ICD) of the cancer cells. Alternatively, other types of photomedicine use photosensitizers to convert absorbed light energy either into reactive oxygen species for photodynamic therapy (PDT) or into heat for photothermal therapy (PTT). ICD is a unique and relevant outcome of NIR‐PIT because it induces long‐lasting antitumor host immunity, which overcomes the immunosuppressive network of cancer. Due to its high specificity and durable antitumor effects, NIR‐PIT is now considered a promising cancer therapy, and optimized NIR‐PIT is readily expanding its applicability to many different types of cancer. Along with the traditional method of NIR‐PIT, new avenues in its realm of treatment are currently being explored, such as the targeting of other immunosuppressive elements, delivery of NIR light through a catheter, real‐time imaging for tumor detection, and the use of tumor‐seeking small molecules for improved efficacy and safety. In addition, its effect on hyperpermeability has opened a door for a wide array of combination therapies with other modalities. This review summarizes the recent findings in clinical and preclinical studies of NIR‐induced photomedicine and its future significance in the field of cancer research.

1 June 2024 in Stroke
Verified
Journal Article
Closed access
SYShinya Yokomizo
Shinya Yokomizo
TKTimo Kopp
Timo Kopp
MRMalte Roessing
Malte Roessing
AMAtsuyo Morita
Atsuyo Morita
SLSeeun Lee
Seeun Lee
Dmitriy AtochinDmitriy Atochin
Dmitriy Atochin
BACKGROUND: The current management of patients with stroke with intravenous thrombolysis and endovascular thrombectomy is effective only when it is timely performed on an appropriately selected but minor fraction of patients. The development of novel adjunctive therapy is highly desired to reduce morbidity and mortality with stroke. Since endothelial dysfunction is implicated in the pathogenesis of stroke and is featured with suppressed endothelial nitric oxide synthase (eNOS) with concomitant nitric oxide deficiency, restoring endothelial nitric oxide represents a promising approach to treating stroke injury. METHODS: This is a preclinical proof-of-concept study to determine the therapeutic effect of transcranial treatment with a low-power near-infrared laser in a mouse model of ischemic stroke. The laser treatment was performed before the middle cerebral artery occlusion with a filament. To determine the involvement of eNOS phosphorylation, unphosphorylatable eNOS S1176A knock-in mice were used. Each measurement was analyzed by a 2-way ANOVA to assess the effect of the treatment on cerebral blood flow with laser Doppler flowmetry, eNOS phosphorylation by immunoblot analysis, and stroke outcomes by infarct volumes and neurological deficits. RESULTS: Pretreatment with a 1064-nm laser at an irradiance of 50 mW/cm 2 improved cerebral blood flow, eNOS phosphorylation, and stroke outcomes. CONCLUSIONS: Near-infrared II photobiomodulation could offer a noninvasive and low-risk adjunctive therapy for stroke injury. This new modality using a physical parameter merits further consideration to develop innovative therapies to prevent and treat a wide array of cardiovascular diseases.

14 May 2022 in Advanced Science
Verified
Journal Article
Open access
SYShinya Yokomizo
Shinya Yokomizo
Maged HenaryMaged Henary
Maged Henary
EBEmmanuel R. Buabeng
Emmanuel R. Buabeng
TFTakeshi Fukuda
Takeshi Fukuda
HMHailey Monaco
Hailey Monaco
Hak Soo ChoiHak Soo Choi
Hak Soo Choi
Fluorescence‐guided surgery (FGS) aids surgeons with real‐time visualization of small cancer foci and borders, which improves surgical and prognostic efficacy of cancer. Despite the steady advances in imaging devices, there is a scarcity of fluorophores available to achieve optimal FGS. Here, 1) a pH‐sensitive near‐infrared fluorophore that exhibits rapid signal changes in acidic tumor microenvironments (TME) caused by the attenuation of intramolecular quenching, 2) the inherent targeting for cancer based on chemical structure (structure inherent targeting, SIT), and 3) mitochondrial and lysosomal retention are reported. After topical application of PH08 on peritoneal tumor regions in ovarian cancer‐bearing mice, a rapid fluorescence increase (< 10 min), and extended preservation of signals (> 4 h post‐topical application) are observed, which together allow for the visualization of submillimeter tumors with a high tumor‐to‐background ratio (TBR > 5.0). In addition, PH08 is preferentially transported to cancer cells via organic anion transporter peptides (OATPs) and colocalizes in the mitochondria and lysosomes due to the positive charges, enabling a long retention time during FGS. PH08 not only has a significant impact on surgical and diagnostic applications but also provides an effective and scalable strategy to design therapeutic agents for a wide array of cancers.

27 November 2025 in Advanced Science
Verified
Journal Article
Open access
SYShinya Yokomizo
Shinya Yokomizo
MMMegi Maci
Megi Maci
ASApril M. Stafford
April M. Stafford
MMMorgan R. Miller
Morgan R. Miller
SPStephen J. Perle
Stephen J. Perle
KKKsenia V. Kastanenka
Ksenia V. Kastanenka
In addition to dementia, Alzheimer's patients suffer from sleep impairments and aberrations in sleep‐dependent brain rhythms. Deficits in inhibitory GABAergic interneuron function disrupt one of those rhythms, slow oscillation in particular, and actively contribute to Alzheimer's progression. The degree to which transplantation of healthy donor interneuron progenitors restores slow oscillation rhythm in young APP/PS1 mice is tested. Medial ganglionic eminence (MGE) progenitors are harvested from mouse embryos and transplanted them into host APP/PS1 mutant cortices. 3D light‐sheet and structured illumination microscopy revealed that transplanted MGE progenitors survived and matured into healthy interneurons. In vivo multiphoton calcium imaging and voltage‐sensitive dye imaging showed functional integration and slow oscillation rescue in the absence or presence of optogenetic stimulation. The work provides proof‐of‐concept evidence that stem cell therapy may serve as a viable strategy to rescue functional impairments in cortical circuits of APP/PS1 mice and potentially those of Alzheimer's patients.

4 September 2025 in bioRxiv
Verified
Preprint
Open access
LYLu Yu
Lu Yu
SYShinya Yokomizo
Shinya Yokomizo
TDTri H. Doan
Tri H. Doan
QZQiuchen Zhao
Qiuchen Zhao
AGAkshatha Ganne
Akshatha Ganne
KKKsenia V. Kastanenka
Ksenia V. Kastanenka
STRUCTURED INTRODUCTION: Deficits in Non-Rapid Eye Movement (NREM) sleep facilitate Alzheimer’s disease (AD) progression. Enhancing GABAergic signaling can restore sleep. Unbiased computational analysis identified zolpidem as high-affinity GABA receptor modulator facilitating chloride transport that could slow AD. METHODS: Zolpidem’s effects on sleep and Alzheimer’s progression were evaluated in young APP/PS1 mice. Sleep was monitored with EEG/EMG telemetry. Widefield imaging with voltage-sensitive dyes was used to track sleep-dependent brain rhythms. Multiphoton microscopy allowed assessments of amyloid plaque load and basal neuronal calcium levels. Behavioral assays were used to measure memory and cognitive function. RESULTS: Zolpidem restored NREM sleep and rescued sleep-dependent brain rhythm, slow oscillation. Zolpidem administration reduced cortical amyloid plaque burden, mitigated neuronal calcium overload, and enhanced sleep-dependent memory consolidation without adverse effects on locomotion. DISCUSSION: Zolpidem effectively slowed Alzheimer’s progression in young APP/PS1 mice. This supports zolpidem’s therapeutic promise as an intervention strategy at early stages of AD.

11 March 2026 in Alzheimer's & Dementia
Verified
Journal Article
Open access
LYLu Yu
Lu Yu
SYShinya Yokomizo
Shinya Yokomizo
TDTri H. Doan
Tri H. Doan
QZQiuchen Zhao
Qiuchen Zhao
AGAkshatha Ganne
Akshatha Ganne
KKKsenia V. Kastanenka
Ksenia V. Kastanenka
INTRODUCTION: Deficits in non–rapid eye movement (NREM) sleep facilitate Alzheimer's disease (AD) progression. Enhancing gamma‐aminobutyric acid‐ergic (GABAergic) signaling can restore sleep. Unbiased computational analysis identified zolpidem as high‐affinity GABA receptor modulator facilitating chloride transport that could slow AD. METHODS: Zolpidem's effects on sleep and Alzheimer's progression were evaluated in young APP/PS1 (amyloid precursor protein/presenilin 1) mice. Sleep was monitored with electroencephalography/electromyography (EEG/EMG) telemetry. Wide‐field imaging with voltage‐sensitive dyes (VSDs) was used to track sleep‐dependent brain rhythms. Multiphoton microscopy allowed assessments of amyloid plaque load and basal neuronal calcium levels. Behavioral assays were used to measure memory and cognitive function. RESULTS: Zolpidem restored NREM sleep and rescued sleep‐dependent brain rhythm, slow oscillation. Zolpidem administration reduced cortical amyloid plaque burden, mitigated neuronal calcium overload, and enhanced sleep‐dependent contextual recall without adverse effects on locomotion. DISCUSSION: Zolpidem effectively decreased amyloid in young APP/PS1 mice. This supports zolpidem's therapeutic promise as an intervention strategy at early stages of AD. Highlights: Zolpidem treatment improves non–rapid eye movement (NREM) sleep stability and reduces sleep fragmentation. Zolpidem restores slow oscillation in young APP/PS1 (amyloid precursor protein/presenilin 1) mice. Zolpidem treatment reduces amyloid plaque burden and calcium overload in neurons. Zolpidem‐treated mice show improved sleep‐dependent memory consolidation. Sleep rhythm enhancement shows promise for Alzheimer's therapy.